Readings Newsletter
Become a Readings Member to make your shopping experience even easier.
Sign in or sign up for free!
You’re not far away from qualifying for FREE standard shipping within Australia
You’ve qualified for FREE standard shipping within Australia
The cart is loading…
The Biology of Ageing: From Hallmarks to Drugs provides a series of reviews covering multiple aspects of the translational pipeline as interventions in the biology of ageing itself become a clinical reality. New chapters cover Cellular senescence and NAD+: what are the links?, Biomarker for ageing: potential and pitfalls, What chemists offer to ageing research, You are what you eat - or are you? Exploring dietary versus topical anti-oxidants in skin ageing, Clinical trials: A simple guide for gerontologists, Towards an ethical framework for geroscience, and more.
The book explores links between known ageing mechanisms and new interventions, agents and actions at the nutraceutical-drug divide, the challenges and opportunities provided by biomarkers and chemistry- biology interface and lastly the ethical and operational challenges of clinical trials in the age of translational geroscience.
$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout
The Biology of Ageing: From Hallmarks to Drugs provides a series of reviews covering multiple aspects of the translational pipeline as interventions in the biology of ageing itself become a clinical reality. New chapters cover Cellular senescence and NAD+: what are the links?, Biomarker for ageing: potential and pitfalls, What chemists offer to ageing research, You are what you eat - or are you? Exploring dietary versus topical anti-oxidants in skin ageing, Clinical trials: A simple guide for gerontologists, Towards an ethical framework for geroscience, and more.
The book explores links between known ageing mechanisms and new interventions, agents and actions at the nutraceutical-drug divide, the challenges and opportunities provided by biomarkers and chemistry- biology interface and lastly the ethical and operational challenges of clinical trials in the age of translational geroscience.